ImmunityBio, Inc. (IBRX) Expands ANKTIVA Access With First Commercial Use in Saudi Arabia [Yahoo! Finance]
ImmunityBio, Inc. (IBRX)
Company Research
Source: Yahoo! Finance
TheFly reported on April 21 that ImmunityBio, Inc. (NASDAQ:IBRX) announced that its immunotherapy ANKTIVA has begun commercial availability in Saudi Arabia, with initial patients already identified for treatment. The therapy is being used in approved indications, including bladder cancer, in combination with Bacillus Calmette-Guérin for adults with BCG-unresponsive non-muscle invasive disease, as well as in metastatic non-small cell lung cancer when combined with an immune checkpoint inhibitor. Both uses have been authorized by the Saudi Food and Drug Authority. Distribution in the region is being handled through partnerships with Biopharma and Cigalah Healthcare, supported by the company's local Saudi subsidiary. The launch marks an expansion of access to ANKTIVA across the Middle East, advancing its presence in oncology care settings. ImmunityBio, Inc. (IBRX) Expands ANKTIVA Access With First Commercial Use in Saudi Arabia Separately, earlier on March 31, IBRX announced it ha
Show less
Read more
Impact Snapshot
Event Time:
IBRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IBRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IBRX alerts
High impacting ImmunityBio, Inc. news events
Weekly update
A roundup of the hottest topics
IBRX
News
- IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law FirmGlobeNewswire
- IBRX DEADLINE: The Gross Law Firm Reminds ImmunityBio, Inc. Investors of Upcoming Securities Class Action DeadlineGlobeNewswire
- IBRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ImmunityBio, Inc. Investors Have Opportunity to Lead Class Action Lawsuit!ACCESS Newswire
- Pomerantz LLP Issues Reminder to Shareholders in ImmunityBio, Inc. of Class Action – IBRXACCESS Newswire
- ImmunityBio, Inc. Securities Fraud Class Action Result of FDA Warning and 21% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLCACCESS Newswire
IBRX
Earnings
- 5/12/25 - Miss
IBRX
Sec Filings
- 4/9/26 - Form 8-K
- 4/6/26 - Form 8-K
- 4/2/26 - Form 4
- IBRX's page on the SEC website